In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Team

Editorial Team

The policy and regulatory insights advantage for biopharma decision-makers around the globe.

Latest From Pink Sheet Team

Pink Sheet Podcast: FDA And Psychedelic Drugs, Aduhelm Clinical Trial Data, Adcomm Candidates

Pink Sheet reporters and editors discuss the FDA’s approach to psychedelic drugs, whether postmarket clinical trial data from the Alzheimer’s drug Aduhelm will be published, and the FDA offering more time to find candidates for its new Genetic Metabolic Diseases Advisory Committee.

Neurology Post Market Regulation & Studies

Pink Sheet Podcast: Price Negotiation Suit Tossed, Drug Shortage Probe, FDA-Approved Marijuana

Pink Sheet reporters and editors discuss the dismissal of PhRMA’s suit challenging the Medicare price negotiation provisions, the US FTC and HHS investigation of drug shortages, and the potential for FDA-approved marijuana products.

Pricing Debate Generic Drugs

Pink Sheet Podcast: US FDA Adcomm Schedule, CMS And Drug Importation, Missed User Fee Goals

Pink Sheet reporters and editors discuss the nearly wide open 2024 FDA advisory committee calendar, CMS’s impact on Florida’s drug importation plan, and the FDA’s many missed user fee goals in 2023.

Advisory Committees Pricing Debate

In Case You Missed In It: News On FDA’s Foreign Offices, Decentralized Clinical Trials, And More

We clean out your MLK Day inbox so you don’t have to.

Pink Sheet Podcast: Taking A Look Back, And Forward, With US FDA’s Project Orbis

Pink Sheet reporters and editors in the US and Europe consider the growth and impact of Project Orbis after a year in which two major regulators joined the program, but several countries did not keep up with the US approval pace.

Market Access Drug Review

Pink Sheet Podcast: Janet Woodcock Retiring, Accelerated Approval Reform, US FDA Meeting Recording Policy

Pink Sheet reporters and editors discuss US FDA Principal Deputy Commissioner Janet Woodcock’s legacy as her retirement approaches, the stance of the FDA’s oncology division on confirming benefit after an accelerated approval, and why formal meetings between the agency and sponsors cannot be recorded.

Leadership Review Pathway
See All
UsernamePublicRestriction

Register